Program

Click here to download the SSM7 program

SSM7– UNIVERSITE DE MONTREAL – JUNE 14-19, 2015

SUNDAY, JUNE 14, 2015

Pavilion Jean-Coutu, room S1-111

15:00 – 16:00     Registration

16:00 – 16:15     OFFICIAL OPENING – 7th Summer School on Medicines (SSM7)

Denis de Blois, Université de Montréal, Québec, Chairman, SSM7
Brian White-Guay, Université de Montréal, Québec
Jordi Quintana, Parc Cientific Barcelona (PCB)
Pierre Cordelier, Université Paul-Sabatier / INSERM, Toulouse
Remy Poupot, Université Paul-Sabatier / INSERM, Toulouse

16:15 – 17:15     Keynote Lecture 1 : Dendrogenin A: a tumor suppressor metabolite and an example of transfer from academia to the industry

Marc Poirot, Inserm / CNRS / Université Paul Sabatier

17:15 – 18:15     Keynote Lecture 2 : The challenge of developing a therapy for an orphan disease as a Canadian startup: the story of Enobia

Philippe Crine, Founder and CSO, Enobia Pharma

18:15 – 20:00     Welcome Reception at Pavilion Jean-Coutu


MONDAY, JUNE 15, 2015

Pavilion Jean-Coutu, room S1-111

SESSION I: DRUG R&D, AN OVERVIEW FROM IDEA TO MARKET

Chairperson: Denis deBlois, Université de Montréal, Québec

8:45 – 10:15     Drug Discovery overview

Denis deBlois, Université de Montréal, Québec

10:15 – 10:30     Health break

10:30 – 12:00     Drug Development overview

Brian White-Guay, Université de Montréal, Québec

12:00 – 13:15     Lunch

13:15 – 14:45     Molecules and Money: the Business of Drug Development

Luc Vachon, Clinical and Product Development Advisor, Ex-CEO Asmacure, Ex-President BioQuébec

14:45 – 15:45     Novel, non obvious, useful? Intellectual property as a discovery engine

Steven Lam, PhD, patent agent, ROBIC, S.E.N.C.R.L.

15:45 – 16:15     Plenary discussion with speakers

16:15 – 16:30     Health break

16:30 – 17:30     Visit of IRIC Drug Discovery Platforms (HTS– Medicinal chemistry – SAR– Cytometry)

Manon Valiquette, Chief manager, IRIC Scientific & Technology Platforms


TUESDAY, JUNE 16, 2015

Pavilion Jean-Coutu, room S1-111

SESSION II: FROM DRUG TARGET TO NONCLINICAL DEVELOPMENT

Chairperson: Jordi Quintana, Parc Centific Barcelona (PCB)

8:45 – 9:45       A molecular pharmacologist’s guide to X-ray crystallography

Xavier Deupi, Paul Scherrer Institute

9:45 – 10:45     Drug discovery – small molecule

Jordi Quintana, Parc Cientific Barcelona (PCB)

10:45 – 11:00     Health break

11:00 – 12:00     Chemistry-fabrication-formulation of small molecules / biologics

Grégoire Leclair, Université de Montréal

12:00 – 13:15     Lunch

13:15 – 14:15     Current Trends in Non-Clinical Safety Testing

Céline Locas, Consultant in Toxicology and Drug Development

14:15 – 15:15     Dendrimers as Drug : from idea to preclinical development

Rémy Poupot, Université Paul-Sabatier / INSERM, Toulouse

15:15 – 15:45     Plenary discussion with speakers

15:45 – 16:00     Health break

SESSION III : PARTICIPANT MINI-SYMPOSIUM

Chairperson: Pierre Cordelier, Université Paul-Sabatier/ INSERM, Toulouse

16:00 – 17:00     Participant short presentations – “How does my current research fit in the context of drug R&D ?” 


WEDNESDAY, JUNE 17, 2015

Pavilion Jean-Coutu, room S1-111

SESSION IV FROM CLINICAL DEVELOPMENT TO MARKET ACCESS

Chairperson: Brian White-Guay, Université de Montréal, Québec

8:45 – 9:45     Learning studies : From first in man to proof of concept studies

Marc Lefebvre, VP, Algorithme Pharma

9:45 – 10:45   Confirmatory studies

Brian White-Guay, Université de Montréal, Québec

10:45 – 11:00     Health break

11:00 – 12:00     Pharmaco-economics and Market Access

Jean Lachaine, Université de Montréal, Québec

12:00 – 13:15     Lunch

13:15 – 14:15     Pharmacovigilance and Risk Management Planning

Ariel Arias, Senior Advisor, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Invited professor, Université de Montréal

14:15 – 14:45     Plenary discussion with speakers

14:45 – 15:00     Health break

SESSION V : CASE STUDY I – REGULATORY STRATEGIES

15:00 – 17:15     Development of a novel agent for inflammatory liver diseases

Patrick Colin, Chief Development Officer, Verlyx Pharma 


THURSDAY, JUNE 18, 2015

Pavilion Jean-Coutu, room S1-111

SESSION VI : INDUSTRIAL SYMPOSIUM

THE NEW DRUG DEVELOPMENT COLLABORATION LANDSCAPE IN QUÉBEC

in collaboration with CiToxLAB

Chairperson: Jean-Pierre Moreau, Business development, CiToxLAB North America Inc.

Opening Remarks: Jean-Pierre Moreau, Chairman, CiToxLAB

9:30 – 10:15  From academia to the clinic : Discovery of a new molecule that expands stem cells from umbilical cord blood

Anne Marinier, Ph.D., IRIC Montréal

10:15 – 10:45  Assessment of Hematotoxicity in Preclinical Studies

Virginie Allegret, Ph.D., CiToxLAB

10:45 – 11:00  Health break

11:00 – 11:30  Custom-designed projects to establish the proof of concept of innovation bioactive molecules

Esther Millette, Ph.D., Transbiotech, Levis

11:30 – 13:30  Lunch

13:30 – 14:10  Dose concepts for Photodynamic Therapy and other Light based Therapies

Lothar Lilge, Ph.D., University Health Network, University of Toronto

14:15- 15:10 Pain peptides for the validation of the treatment of chronic pain using natural drugs

Pascal Vachon, Ph.D., Faculté de Médecine vétérinaire, Université de Montréal

15:10 – 15:25  Health break

15:25 – 16:10  gIcare pharma to Inversago: how to reach human proof of efficacy

Maxime Ranger, Ph.D., MBA, Drug Development Strategist, Serial Entrepreneur

16:10 – 16:45  Neomed II, a new opportunity for the advancement of Biologics in Quebec

Philippe Walker, Ph.D., Neomed Institute

Networking cocktail

FRIDAY, JUNE 19, 2015

Pavilion Jean-Coutu, room S1-111

SESSION VII : CASE STUDIES : FROM IDEA TO MARKET

Treatment of moderate to severe psoriasis : The challenges that represented this therapeutic area, the chemical, preclinical and clinical development of our treatment and the pharmacoeconomical strategy behind it.

Chairperson: Louise Fortier, Université de Montréal, Québec

9:00 – 10:30    Company A

Alumni of the Advanced Graduate Diploma in Drug development at Faculty of pharmacy, Université de Montréal : Meryem Bardaoui, Véronick Brûlé Viau, Fanny Desjardins, Vincent Lague, François Péloquin, Sina Pousht-Mashhad and Marc-André Sauriol

10:30 – 10:45   Health break

10:45 – 12:15    Company B

Alumni of the Advanced Graduate Diploma in Drug development at Faculty of pharmacy, Université de Montréal : Yousef Hanna, Mickaël Martinho Lemay, Sania Sanji, Hadi Mazloum, Roxanne Julien, Maria Eugenia Juarez Ugarte, Lyna Benaouda, Ahmedi Mohamed, Chung-Yan Yuen, Aurore Flandrin and Mina Guirguis

12:15 – 13:30   Lunch

SESSION VIII : CARING ABOUT CAREERS: NAVIGATING THE ECOSYSTEM OF BIOPHARMA

Chairperson:  Pierre Cordelier, Université Paul-Sabatier

13:30 – 14:30   Biopharmaceutical Stakeholders: understanding the life science ecosystem

Michelle Savoie, CEO, Montréal InVivo

14:30 – 15:30   Career development in the biopharmaceutical sector

Luc Vachon, Clinical and Product Development Advisor, Ex-CEO Asmacure, Ex-President BioQuébec

15:30 – 16:00   Plenary discussion with speakers

16:00 – 16:30   SSM7 Wrap-up, Closing comments and Overture towards SSM8

Denis de Blois, Université de Montréal, Québec, Chairman, SSM7
Brian White-Guay, Université de Montréal, Québec
Louise Fortier, Université de Montréal, Québec
Pierre Cordelier, Université Paul-Sabatier / INSERM, Toulouse
Remy Poupot, Université Paul-Sabatier / INSERM, Toulouse